ARS Pharmaceuticals, Inc. logo SPRY - ARS Pharmaceuticals, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 1
BUY 3
HOLD 6
SELL 0
STRONG
SELL 0
| PRICE TARGET: $25.50 DETAILS
HIGH: $26.00
LOW: $25.00
MEDIAN: $25.50
CONSENSUS: $25.50
UPSIDE: 349.99%

Stock News

Faruqi & Faruqi, LLP Urges ARS Pharmaceuticals (SPRY) Investors to Seek Counsel Before the October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action

Faruqi & Faruqi, LLP Urges ARS Pharmaceuticals (SPRY) Investors to Seek Counsel Before the October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in ARS Pharmaceuticals to Contact Him Directly to Discuss Their Options New York, New York--(Newsfile Corp. - September 3, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against ARS Pharmaceuticals Inc. (""ARS Pharmaceuticals" or the "Company") (NASDAQ: SPRY). [You may also click here for additional information] WHY: Faruqi & Faruqi, LLP, a leading national securities law firm, informs investors of the federal securities class action on behalf of all investors who purchased or otherwise acquired ARS securities between March 9, 2026, and June 24, 2026, inclusive (the "Class Period").

Sep 03, 2026 09:11 AM • newsfilecorp.com (Hide legal announcements)
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY

New York, New York--(Newsfile Corp. - September 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Sep 02, 2026 07:21 PM • newsfilecorp.com (Hide legal announcements)
ARS Stock Drop: Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Against ARS Pharmaceuticals Inc.

ARS Stock Drop: Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Against ARS Pharmaceuticals Inc.

San Diego, California--(Newsfile Corp. - September 2, 2026) - Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, including anaphylaxis.

Sep 02, 2026 11:36 AM • newsfilecorp.com (Hide legal announcements)
Kaplan Fox Alerts Investors of a Securities Class Action Against ARS Pharmaceuticals Inc. (SPRY) - Deadline is October 5, 2026

Kaplan Fox Alerts Investors of a Securities Class Action Against ARS Pharmaceuticals Inc. (SPRY) - Deadline is October 5, 2026

New York, New York--(Newsfile Corp. - September 2, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in ARS and have suffered losses, you may CLICK HERE to contact us.

Sep 02, 2026 06:00 AM • newsfilecorp.com (Hide legal announcements)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Sep 01, 2026 01:15 PM • globenewswire.com (Hide legal announcements)
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Sep 01, 2026 06:32 AM • globenewswire.com (Hide legal announcements)
SPRY DEADLINE: SueWallSt Reminds ARS Pharmaceuticals Inc. Investors of Upcoming Securities Class Action Deadline

SPRY DEADLINE: SueWallSt Reminds ARS Pharmaceuticals Inc. Investors of Upcoming Securities Class Action Deadline

A securities class action alleges ARS Pharmaceuticals overstated its progress toward removing prior authorization barriers with CVS Caremark, the last major PBM standing between neffy and unrestricted commercial access A securities class action alleges ARS Pharmaceuticals overstated its progress toward removing prior authorization barriers with CVS Caremark, the last major PBM standing between neffy and unrestricted commercial access

Sep 01, 2026 06:17 AM • globenewswire.com (Hide legal announcements)
SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ARS Pharmaceuticals between March 9, 2026 and June 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - September 1, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ARS Pharmaceuticals Inc. (""ARS Pharmaceuticals" or the "Company") (NASDAQ: SPRY) and reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Sep 01, 2026 04:35 AM • newsfilecorp.com (Hide legal announcements)
ROSEN, REGARDED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

ROSEN, REGARDED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline.

Aug 31, 2026 05:56 PM • globenewswire.com (Hide legal announcements)
ROSEN, A LONGSTANDING FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY

ROSEN, A LONGSTANDING FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY

New York, New York--(Newsfile Corp. - August 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Aug 31, 2026 05:31 PM • newsfilecorp.com (Hide legal announcements)
SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

A securities class action alleges ARS Pharmaceuticals' co-founder and CEO personally steered investors toward a July 1, 2026 CVS Caremark coverage date that never arrived, leaving SPRY shareholders with a 23.9% single-day loss A securities class action alleges ARS Pharmaceuticals' co-founder and CEO personally steered investors toward a July 1, 2026 CVS Caremark coverage date that never arrived, leaving SPRY shareholders with a 23.9% single-day loss

Aug 31, 2026 06:10 AM • globenewswire.com (Hide legal announcements)
Kaplan Fox Notifies ARS Pharmaceuticals Inc. (SPRY) Investors of an Upcoming Lead Plaintiff Deadline on October 5, 2026

Kaplan Fox Notifies ARS Pharmaceuticals Inc. (SPRY) Investors of an Upcoming Lead Plaintiff Deadline on October 5, 2026

New York, New York--(Newsfile Corp. - August 31, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in ARS and have suffered losses, you may CLICK HERE to contact us.

Aug 31, 2026 05:15 AM • newsfilecorp.com (Hide legal announcements)

Price Targets